Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Vascular Biogenics (VBLT)
NASDAQ:VBLT
Vascular Biogenics (VBLT) Stock Price & Analysis
700 Followers
VBLT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.10 - $2.20
Previous Close$0.22
Volume916.47K
Average Volume (3M)1.20M
Market Cap
$15.40M
Enterprise Value-$10.69M
Total Cash (Recent Filing)$26.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.7
Beta1.18
Next Earnings
Aug 17, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding70,500,000
10 Day Avg. Volume827,375
30 Day Avg. Volume1,197,175
Standard Deviation0.19
R-Squared0.04
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.74
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-19.61
Enterprise Value/Gross Profit-19.30
Enterprise Value/Ebitda0.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Vascular Biogenics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VBLT FAQ
What was Vascular Biogenics’s price range in the past 12 months?
Vascular Biogenics lowest stock price was $0.10 and its highest was $2.20 in the past 12 months.
What is Vascular Biogenics’s market cap?
Currently, no data Available
When is Vascular Biogenics’s upcoming earnings report date?
Vascular Biogenics’s upcoming earnings report date is Aug 17, 2023 which is in 74 days.
How were Vascular Biogenics’s earnings last quarter?
Vascular Biogenics released its earnings results on May 15, 2023. The company reported -$0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.034.
Is Vascular Biogenics overvalued?
According to Wall Street analysts Vascular Biogenics’s price is currently Overvalued.
Does Vascular Biogenics pay dividends?
Vascular Biogenics does not currently pay dividends.
What is Vascular Biogenics’s EPS estimate?
Vascular Biogenics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vascular Biogenics have?
Vascular Biogenics has 70,500,114 shares outstanding.
What happened to Vascular Biogenics’s price movement after its last earnings report?
Vascular Biogenics reported an EPS of -$0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vascular Biogenics?
Among the largest hedge funds holding Vascular Biogenics’s share is ARK Investment Management LLC. It holds Vascular Biogenics’s shares valued at N/A.
---
Vascular Biogenics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-86.70%
12-Months-Change
Fundamentals
Return on Equity
-78.20%
Trailing 12-Months
Asset Growth
-50.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vascular Biogenics
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.
---
---